Prostate cancer (PCa) is the most common male malignancy in our population.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Over the past two decades, the prostate specific antigen (PSA) has been widely used for screening, diagnosis and monitoring of prostate cancer. Routine use of PSA has been continuing subject to controversy due to its limited specificity, which is derived from the fact that serum PSA levels are produced in a variety of non-neoplastic conditions. The shortcomings in sensitivity and specificity of PSA have promoted the search for new biomarkers to improve diagnostic performance. The ultimate goal is to get those diagnosing clinically significant prostate tumors and to individualize treatment in this disease. Among the biomarkers studied in prostate cancer we could found tissue biomarkers as well as serum or urine biomarkers. In this paper we proceed to review those serum biomarkers not related to PSA that have been published in the literature.
Mengual L, Musquera M, Ciudin A, Ribal MJ. Are you the author?
Laboratorio de Biología Molecular, Hospital Clínic de Barcelona, España; Servicio de Urología, Hospital Clínic, Universitat de Barcelona, España; Servicio de Urología, Hospital de Mollet, Barcelona. España.
Reference: Arch Esp Urol. 2015 Apr;68(3):229-39.
Article in Spanish.